

FanÃ©lie Jouenne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5605326/publications.pdf>

Version: 2024-02-01

18
papers

213
citations

1478505

6
h-index

1058476

14
g-index

19
all docs

19
docs citations

19
times ranked

369
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 475-480.	2.8	6
2	High-grade trichoblastic carcinoma with sarcomatoid differentiation harboring TP53 and PIK3CA mutations. Annales De Dermatologie Et De Venereologie, 2022, 149, 74-77.	1.0	2
3	Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients. Blood, 2022, 139, 1820-1832.	1.4	30
4	The MAPK Pathway in Pulmonary Langerhans Cell Histiocytosis. Archivos De Bronconeumologia, 2022, , .	0.8	2
5	Custom pyrosequencing assay to detect short <i>BRAF</i> deletions in Langerhans cell histiocytic lesions. Journal of Clinical Pathology, 2021, 74, 533-536.	2.0	0
6	The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. Cancers, 2021, 13, 2243.	3.7	2
7	Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokineticâ€“pharmacodynamic real-life study. Cancer Chemotherapy and Pharmacology, 2021, 88, 427-437.	2.3	5
8	Phase II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i>V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Clinical Cancer Research, 2021, 27, 3876-3883.	7.0	8
9	Conservative management is effective in unicystic ameloblastoma occurring from the neonatal period: A case report and a literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020, 129, e234-e242.	0.4	6
10	Clinical significance of BRAF/NRAS concurrent mutations in a clinicâ€“based metastatic melanoma cohort. British Journal of Dermatology, 2020, 182, 1281-1283.	1.5	3
11	Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples. Rapid Communications in Mass Spectrometry, 2020, 34, e8594.	1.5	9
12	Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. European Respiratory Journal, 2020, 55, 1901190.	6.7	38
13	The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review. Therapie, 2020, 75, 183-193.	1.0	0
14	A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping. Targeted Oncology, 2020, 15, 759-771.	3.6	2
15	Challenges in the diagnosis of primary cutaneous CD 30 + anaplastic largeâ€“cell lymphoma. British Journal of Dermatology, 2019, 182, 233-234.	1.5	2
16	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. Cancers, 2019, 11, 1203.	3.7	10
17	CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker. Cancers, 2019, 11, 1803.	3.7	85
18	Phase III open label multicenter study of PD0332991 in <i>BRAF^{V600mut}</i> metastatic melanoma patients harboring <i>CDKN2A</i> loss and RB1 expression and treated with vemurafenib.. Journal of Clinical Oncology, 2019, 37, 9545-9545.	1.6	3